English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Two large cardiovascular outcome trials of canagliflozin, comprising the  CANVAS  Program, will complete in early 2017: the  CANagliflozin cardioVascular A ssessment  S tudy ( CANVAS ) and the  CANagliflozin cardioVascular A ssessment  S tudy– R enal ( CANVAS‐R ). Accruing data for the sodium glucose co‐transporter 2 ( SGLT2 ) inhibitor class has identified questions and opportunities that were not apparent when the trials were designed. Accordingly, a series of modifications have been made to the planned analyses. These updates will ensure that the data from the  CANVAS  Program will maximize advances in scientific knowledge and patient care. The specification of the analysis strategy prior to knowledge of the trial results, their design by the independent scientific trial  S teering  C ommittee, the detailed  a priori  definition of the analysis plans, and the external review provided by the  US F ood and  D rug  A dministration all provide maximally efficient and robust utilization of the data. The  CANVAS  Program should significantly advance our understanding of the effects of canagliflozin, and the broader  SGLT2  inhibitor class, on a range of important efficacy and safety outcomes.

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials